Biogen and City Therapeutics: No Recent RNAi Partnership Noted

Published 1 days agoBIIB

As of May 27, 2025, there is no publicly available information about a collaboration between Biogen and City Therapeutics to develop RNA interference (RNAi) therapies. While both companies are active in the biotech field, this specific partnership has not been reported.

City Therapeutics has been focusing on strategic collaborations with other companies, like Bausch + Lomb, in developing RNAi-based treatments for retinal diseases, including geographic atrophy. Meanwhile, Biogen has forged partnerships, such as the one with C4 Therapeutics, to innovate in neuroscience drug discovery, Reuters reported.

The absence of a partnership between Biogen and City Therapeutics for RNAi therapies does not overshadow the strategic alliances each company has formed in their respective areas. These partnerships highlight ongoing efforts to advance medical treatments through novel biotechnological approaches.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Trump Administration Revokes Major Loan Guarantee for Sunnova Energy

4 minutes agoNOVA

In a significant shift in policy, the Trump administration has annulled a $2.92 billion partial loan guarantee that was previously awarded to Sunnova Energy, a prominent residential solar panel installer in the U.S. Reuters reported that the Department of Energy (DOE) has formally 'de-obligated' the guarantee, releasing the federal government from its financial commitment linked to Project Hestia. Project Hestia, which was announced under President Biden in April 2023, aimed to install nearly 100,000 rooftop solar systems to assist low-income households. It represented the DOE's largest solar financing effort at the time. However, Sunnova's financial struggles became evident earlier this year when the company issued a 'going concern' warning in March 2025, casting serious doubt on its ability to sustain operations over the coming twelve months. Despite these challenges, Sunnova has been exploring other funding options, such as issuing $371 million in bonds backed by the now-revoked loan guarantee, which aren't part of its current restructuring plans. This cancellation by the Trump administration aligns with a broader reassessment of clean energy financing by the DOE, in favor of policies that prioritize the oil and gas industries.

Morgan Stanley to Dispute Dutch Tax Evasion Claims

34 minutes agoMS

Morgan Stanley is gearing up to fight accusations of tax evasion related to dividend taxes in the Netherlands. According to the Dutch Public Prosecution Service, the issue originates from activities between 2009 and 2013, where Morgan Stanley allegedly misreported tax returns, unlawfully offsetting €124 million in withholding tax against €825 million in dividends. Reuters reported that these allegations hold the European parent company, Morgan Stanley, accountable. The Dutch authorities are conducting a criminal investigation, suspecting that the bank has engaged in tax evasion. Meanwhile, Morgan Stanley contests these claims, arguing that the investigation is based on incomplete and misinterpreted information concerning the complex and opaque tax laws they were subject to. This isn't Morgan Stanley's first encounter with the Dutch tax authorities. In 2020, the bank settled a long-standing case with a payment of nearly €200 million over dividend stripping practices. Despite this history, Morgan Stanley insists on challenging the current claims, highlighting the intricacy of international tax regulations and their commitment to resolving the matter comprehensively.

Li Auto Misses Revenue Mark but Exceeds Earnings Expectations in Q4 2024

49 minutes agoLI

Li Auto Inc. recently shared its financial results for the fourth quarter of 2024, revealing a revenue of 44.3 billion Chinese yuan (about $6.07 billion). This figure marked a 6.1% increase from the previous year but fell short of analysts' expectations of 44.6 billion yuan. However, the company reported adjusted net earnings per ADS of 3.79 yuan ($0.52), which were ahead of forecasts of 2.87 yuan. Vehicle deliveries also saw a significant boost, reaching 158,696 units, a 20.4% rise from the prior year, as reported by Benzinga. Li Auto's gross margin dropped by 320 basis points compared to last year, down to 20.3%, affected by a decrease in vehicle margin to 19.7%. Despite this, the company's adjusted income from operations grew by 9.1% to $577.6 million. Adjusted net income faced a 12.0% decline, landing at $553.4 million, although the company maintained a hefty cash position of $15.5 billion at the end of 2024. For the first quarter of 2025, Li Auto projects vehicle deliveries between 88,000 and 93,000 units, suggesting a potential year-over-year increase of 9.5% to 15.7%. The anticipated total revenue is expected to range from 23.4 billion to 24.7 billion yuan ($3.2 billion to $3.4 billion), implying a slight decrease compared to the same period last year. This cautious forecast reflects the company's ongoing strategic efforts to widen its product range and advance its autonomous driving technology, according to reporting from Nasdaq.

SAP's Surge Boosts European Stocks Following Strong Earnings

1 hours agoSAP

SAP's recent performance has notably uplifted European markets, as the software giant's shares jumped 10.6%, marking its most significant gain in six years. This rise comes on the back of SAP surpassing its first-quarter profit expectations, according to a report by Tradingview. The positive earnings report provided a much-needed boost to investor sentiment across Europe. SAP's cloud business has become a powerhouse, with a reported 25% growth in cloud revenue year-over-year. The demand for its Cloud ERP Suite has been a considerable contributor, reflecting the company's successful expansion into digital transformation services. Additionally, the integration of artificial intelligence into SAP's cloud offerings features prominently, as Nasdaq noted, with AI now part of about 30% of its cloud contracts. In a significant leap, SAP's market valuation hit €313 billion, positioning it above Novo Nordisk as Europe's most valuable company, as highlighted by the Financial Times. Meanwhile, the DAX index, which counts SAP as a key component, surged 3.1%. This, combined with easing U.S.-China trade tensions, has helped buoy investor confidence, signaling a bright spot in the European market landscape.